WO2018178243A3 - Dihydrotetrabenazine for use in the treatment a movement disorder - Google Patents

Dihydrotetrabenazine for use in the treatment a movement disorder Download PDF

Info

Publication number
WO2018178243A3
WO2018178243A3 PCT/EP2018/058088 EP2018058088W WO2018178243A3 WO 2018178243 A3 WO2018178243 A3 WO 2018178243A3 EP 2018058088 W EP2018058088 W EP 2018058088W WO 2018178243 A3 WO2018178243 A3 WO 2018178243A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydrotetrabenazine
treatment
movement disorder
tourette
syndrome
Prior art date
Application number
PCT/EP2018/058088
Other languages
French (fr)
Other versions
WO2018178243A2 (en
Inventor
Andrew John Duffield
Anant Pandya
Original Assignee
Adeptio Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1705306.7A external-priority patent/GB201705306D0/en
Priority claimed from GBGB1705305.9A external-priority patent/GB201705305D0/en
Priority claimed from GBGB1705304.2A external-priority patent/GB201705304D0/en
Priority to AU2018241940A priority Critical patent/AU2018241940B2/en
Priority to EP18718398.3A priority patent/EP3606530A2/en
Priority to CA3057548A priority patent/CA3057548A1/en
Application filed by Adeptio Pharmaceuticals Limited filed Critical Adeptio Pharmaceuticals Limited
Priority to CN201880035549.0A priority patent/CN110691596A/en
Priority to RU2019134416A priority patent/RU2768738C2/en
Priority to JP2019553960A priority patent/JP7250692B2/en
Publication of WO2018178243A2 publication Critical patent/WO2018178243A2/en
Publication of WO2018178243A3 publication Critical patent/WO2018178243A3/en
Priority to JP2022194948A priority patent/JP2023029975A/en
Priority to AU2023274089A priority patent/AU2023274089A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

This invention relates to the use of (+)-β-dihydrotetrabenazine and combinations of (+)-α-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and/or (+)-β- dihydrotetrabenazine, for the treatment of movement disorders, such as Tourette's syndrome. The invention also provides dosage forms containing said dihydrotetrabenazine isomers.
PCT/EP2018/058088 2017-04-01 2018-03-29 Pharmaceutical compositions WO2018178243A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2019553960A JP7250692B2 (en) 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in treating movement disorders
RU2019134416A RU2768738C2 (en) 2017-04-01 2018-03-29 USE OF (−)-α-DIHYDROTETRABENAZINE OR A COMBINATION THEREOF WITH (+)-α-DIHYDROTETRABENAZINE IN THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDER, AS WELL AS CORRESPONDING METHODS
CN201880035549.0A CN110691596A (en) 2017-04-01 2018-03-29 Pharmaceutical composition
EP18718398.3A EP3606530A2 (en) 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in the treatment a movement disorder
CA3057548A CA3057548A1 (en) 2017-04-01 2018-03-29 Pharmaceutical compositions
AU2018241940A AU2018241940B2 (en) 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in the treatment a movement disorder
JP2022194948A JP2023029975A (en) 2017-04-01 2022-12-06 Dihydrotetrabenazine for use in treatment of movement disorder
AU2023274089A AU2023274089A1 (en) 2017-04-01 2023-11-28 Dihydrotetrabenazine For Use In The Treatment of a Movement Disorder

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB1705306.7A GB201705306D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GB1705305.9 2017-04-01
GBGB1705304.2A GB201705304D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GB1705304.2 2017-04-01
GB1705306.7 2017-04-01
GBGB1705305.9A GB201705305D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
US201762515940P 2017-06-06 2017-06-06
US201762515935P 2017-06-06 2017-06-06
US201762515930P 2017-06-06 2017-06-06
US62/515,940 2017-06-06
US62/515,935 2017-06-06
US62/515,930 2017-06-06

Publications (2)

Publication Number Publication Date
WO2018178243A2 WO2018178243A2 (en) 2018-10-04
WO2018178243A3 true WO2018178243A3 (en) 2018-12-13

Family

ID=63674294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/058088 WO2018178243A2 (en) 2017-04-01 2018-03-29 Pharmaceutical compositions

Country Status (7)

Country Link
EP (1) EP3606530A2 (en)
JP (2) JP7250692B2 (en)
CN (1) CN110691596A (en)
AU (2) AU2018241940B2 (en)
CA (1) CA3057548A1 (en)
RU (2) RU2022104034A (en)
WO (1) WO2018178243A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051834A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
CN116492340A (en) 2017-10-10 2023-07-28 纽罗克里生物科学有限公司 Methods of administering certain VMAT2 inhibitors
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB800969A (en) * 1956-02-08 1958-09-03 Hoffmann La Roche Novel 2-hydroxy-benzo [ª‡] quinolizines, acid addition salts thereof and a process for the manufacture of same
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2010018408A2 (en) * 2008-08-12 2010-02-18 Biovail Laboratories International (Barbados) Srl Pharmaceutical compositions
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN102285984B (en) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 Preparation method of (2R, 3R, 11bR)-dihydrotetrabenazine and relevant compounds
IN2015DN01662A (en) * 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB800969A (en) * 1956-02-08 1958-09-03 Hoffmann La Roche Novel 2-hydroxy-benzo [ª‡] quinolizines, acid addition salts thereof and a process for the manufacture of same
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2010018408A2 (en) * 2008-08-12 2010-02-18 Biovail Laboratories International (Barbados) Srl Pharmaceutical compositions
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JACK J CHEN ET AL: "Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 34, no. 7, 7 June 2012 (2012-06-07), pages 1487 - 1504, XP028405380, ISSN: 0149-2918, [retrieved on 20120620], DOI: 10.1016/J.CLINTHERA.2012.06.010 *
KARL G. BOLDT ET AL: "Synthesis of (+)- and (-)-Tetrabenazine from the Resolution of [alpha]-Dihydrotetrabenazine", SYNTHETIC COMMUNICATIONS, vol. 39, no. 20, 18 September 2009 (2009-09-18), PHILADELPHIA, PA; US, pages 3574 - 3585, XP055423935, ISSN: 0039-7911, DOI: 10.1080/00397910902788125 *
KILBOURN ET AL: "Rat pancreas uptake of [<11>C]dihydrotetrabenazine stereoisomers", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 37, no. 8, 1 November 2010 (2010-11-01), pages 869 - 871, XP027472058, ISSN: 0969-8051, [retrieved on 20100724], DOI: 10.1016/J.NUCMEDBIO.2010.06.001 *
YAO ET AL: "Preparation and evaluation of tetrabenazine enantiomers and all eight stereoismores of dihydrotetrabenazine as VMAT2 inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,, vol. 46, 1 January 2011 (2011-01-01), pages 1841 - 1848, XP002781076 *

Also Published As

Publication number Publication date
JP7250692B2 (en) 2023-04-03
WO2018178243A2 (en) 2018-10-04
RU2019134416A (en) 2021-05-04
RU2768738C2 (en) 2022-03-24
JP2020512987A (en) 2020-04-30
RU2019134416A3 (en) 2021-08-18
JP2023029975A (en) 2023-03-07
EP3606530A2 (en) 2020-02-12
AU2018241940A1 (en) 2019-10-03
AU2023274089A1 (en) 2023-12-14
RU2022104034A (en) 2022-03-05
CN110691596A (en) 2020-01-14
AU2018241940B2 (en) 2023-09-28
CA3057548A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
AU2018284960A1 (en) AADC polynucleotides for the treatment of Parkinson&#39;s disease
MX2018002990A (en) Use of pasteurized akkermansia for treating metabolic disorders.
MD20170035A2 (en) Compositions and methods of use for treating matabolic disorders
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
PH12015502788A1 (en) Antibody formulations and methods
MX2017013562A (en) Microbiome regulators and related uses thereof.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MD20170020A2 (en) Compositions and methods of use for treating metabolic disorders
PH12019502002A1 (en) Combination theraphy
EP3411504A4 (en) Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
MX2020006237A (en) Compounds for treatment of diseases related to dux4 expression.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2022001061A (en) Interleukin-2 agents and uses thereof.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2020004666A (en) Compositions and methods for the treatment of eye disorders.
MX2020007555A (en) Factor h potentiating antibodies and uses thereof.
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
MX2020001256A (en) Compounds for the prevention and treatment of medical disorders and uses thereof.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2017013879A (en) Compositions comprising anakinra.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18718398

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3057548

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019553960

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018241940

Country of ref document: AU

Date of ref document: 20180329

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018718398

Country of ref document: EP

Effective date: 20191104